Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Journal of Antimicrobial Chemotherapy(2021)10.1093/jac/dkab494Source: DataRank Database

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia is a research paper published in Journal of Antimicrobial Chemotherapy (2021). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.71)OA: greenTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Jean‐François Timsit,Marin H. Kollef ORCID,Richard G. Wunderink ORCID,Nobuaki Shime ORCID,Martin Nováček ORCID

Live enrichment

PubMed:35022730 PMC:PMC9432134 OpenAlex:https://openalex.org/W4206455938

NIAID NIH HHS

Grant: U19 AI135964

The Lockwood Group

NIH

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

FWCI

1.71

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9432134

publisherhttps://academic.oup.com/jac/article-pdf/77/4/1166/45632655/dkab494.pdf

journalhttps://doi.org/10.1093/jac/dkab494

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35022730

Fields of Study

Nosocomial Infections in ICUAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAnti-Bacterial AgentsCephalosporinsHospitalsHumansMeropenemMicrobial Sensitivity TestsPneumonia, BacterialProspective StudiesPseudomonas aeruginosaTazobactamVentilators, Mechanical

MeSH Terms

MeropenemTazobactamAnti-Bacterial AgentsCephalosporinsHospitalsHumansMicrobial Sensitivity TestsProspective StudiesPseudomonas aeruginosaVentilators, MechanicalPneumonia, Bacterial

Keywords

MeropenemMedicineTazobactamHospital-acquired pneumoniaPneumoniaVentilator-associated pneumoniaPopulationKlebsiella pneumoniaeMicrobiologyInternal medicinePseudomonas aeruginosaBacterial pneumoniaAntibioticsBiologyAntibiotic resistanceBacteriaEscherichia coli

Sustainable Development Goals

SDG 0: Good health and well-being